تصدی مدیریت ارشد تیم و اختراع تکنولوژیکی در شرکت های بیوتکنولوژی پست ـ IPO
|کد مقاله||سال انتشار||مقاله انگلیسی||ترجمه فارسی||تعداد کلمات|
|4602||2012||8 صفحه PDF||سفارش دهید||6562 کلمه|
Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)
Journal : Journal of Business Research, Volume 65, Issue 9, September 2012, Pages 1349–1356
We examine how top management teams (TMTs) facilitate invention performance. We test our hypotheses with a sample of 185 biotech firms that issued initial public offerings (IPOs) between 1980 and 1997. We predict that the percentage of founders on TMT has an inverted U-shaped relationship with invention performance. Average intrafirm tenure will be negatively associated with invention performance and average TMT member experiences from competitors or outside the industry will be positively associated with invention performance. Finally, contextual factors such as firm size and firm age moderate the impact of TMT experiences on invention performance.
Top management teams have attracted research attention as an antecedent of organizational outcomes. Researchers using the upper echelons perspective (Hambrick & Mason, 1984) have shown top managers have a significant impact on a variety of organizational outcomes, such as strategic change (Barker and Barr, 2002 and Musteen et al., 2006), firm growth (Kor, 2003 and Stam and Elfring, 2008), search (Papenhausen, 2010), acquisition performance (Walters, Kroll, & Wright, 2007), and innovation (Alexiev et al., 2010, Elenkov et al., 2005, Smith and Tushman, 2005, Vaccaro et al., forthcoming and Wu et al., 2005). While much research has focused on established public firms, less research has examined the unique context of a newly public firm. The initial public offering (IPO) is an important milestone in an entrepreneurial firm's life cycle (Carpenter et al., 2003 and Filatotchev and Piesse, 2009). The post-IPO firm is unique because it has already laid foundations for further development, unlike the early-stage firm that prioritizes on survival amid high uncertainties. At the same time, its legitimacy is lacking and its technological and market base are yet to grow (Filatotchev & Piesse, 2009). The post-IPO firm faces transitional challenges such as liability of adolescence (Hannan, 1998). The post-IPO TMT is in a unique position relative to their peers at either an early-stage firm or a well-established public firm. The TMT often continues to be influenced by a sizable presence of founders, rarely seen in a mature public firm; it has also included external managers who established their career paths elsewhere to enrich the experiences of the TMT, which does not happen to the early-stage firm that primarily relies on founders. The TMT in the post-IPO firm becomes the locus where external and internal managerial experiences are brought together, with far-reaching implications. We examine the role of TMT using an organizational life cycle perspective (Kazanjian, 1988 and Smith and Miner, 1983). We focus on multiple aspects of top managers' experiences such as founder percentage, intrafirm tenure, competitor tenure and outside industry tenure that may better respond to the stage-specific organizational challenges. First, we propose founders' presence has an inverted U-shaped relationship with the firm's patented inventions. Second, we predict that shorter intrafirm tenure, more experiences at competitors (i.e., other firms in the same industry), and more experiences from outside the industry would enhance invention performance. Finally, we highlight organizational contexts and predict that firm age and firm size moderate the relationship between external experiences and invention performance. We test our hypotheses with a sample of 185 biotechnology firms that undertook IPOs between 1980 and 1995. We conclude the paper by discussing the implications of our results.
نتیجه گیری انگلیسی
We synthesize the upper echelons research with the organizational life cycle theory and examine the effects of different aspects of TMT tenure on the invention performance of post-IPO biotechnology firms. We found a curvilinear relationship between the founder percentage and invention performance. Invention performance benefits from shorter intrafirm tenure and more competitor tenure. In addition, organizational contextual factors such as firm age and firm size moderate the effects of competitor tenure and outside industry tenure.